Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male

Hanmi Pharmaceutical

Status: Completed

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01688193

HM-ESNP-102

Details and patient eligibility

About

The purpose of this study is to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male

Enrollment: 68 patients

Sex: Male

Ages: 20 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• BMI: 18.0 - 27.0 kg/m2
• Willingness to sign the written Informed Consent Form

Exclusion criteria

• Evidence of clinically relevant pathology
• History of relevant drug and food allergies
• Positive screen on drugs of abuse
• Participation in a drug study within 60 days prior to drug administration.

Trial design

68 participants in 2 patient groups

HCP 1004

Vimovo 500/20mg